Literature DB >> 8649584

The Clinical Dementia Rating scale: community-based validation of "profound' and "terminal' stages.

G Dooneief1, K Marder, M X Tang, Y Stern.   

Abstract

The original version of the Clinical Dementia Rating (CDR) scale correlates with other dementia rating scales, and predicts nursing home (NH) admission and death. To validate the extended components of the scale, we analyzed data from subjects participating in a community-based study of dementia. The extended CDR scale also correlated with measures of dementia severity and NH residence. "Profound" and "terminal" stages predicted shortened survival. The extended CDR scale should be useful in studies of the later stages of dementia.

Entities:  

Mesh:

Year:  1996        PMID: 8649584     DOI: 10.1212/wnl.46.6.1746

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Effects of general medical health on Alzheimer's progression: the Cache County Dementia Progression Study.

Authors:  Jeannie-Marie S Leoutsakos; Dingfen Han; Michelle M Mielke; Sarah N Forrester; JoAnn T Tschanz; Chris D Corcoran; Robert C Green; Maria C Norton; Kathleen A Welsh-Bohmer; Constantine G Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-06-12       Impact factor: 3.878

2.  Estimation and validation of a multiattribute model of Alzheimer disease progression.

Authors:  Eric Stallard; Bruce Kinosian; Arthur S Zbrozek; Anatoliy I Yashin; Henry A Glick; Yaakov Stern
Journal:  Med Decis Making       Date:  2010 Nov-Dec       Impact factor: 2.583

3.  Association of ApoE and LRP mRNA levels with dementia and AD neuropathology.

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Neurobiol Aging       Date:  2011-06-15       Impact factor: 4.673

4.  Radial width of the temporal horn: a sensitive measure in Alzheimer disease.

Authors:  Giovanni B Frisoni; Cristina Geroldi; Alberto Beltramello; Angelo Bianchetti; Giuliano Binetti; Giovanni Bordiga; Charles DeCarli; Mikko P Laakso; Hilkka Soininen; Cristina Testa; Orazio Zanetti; Marco Trabucchi
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

5.  A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.

Authors:  Frederick A Schmitt; Christine H Wichems
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

6.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care.

Authors:  Stephanie Behrens; Gail B Rattinger; Sarah Schwartz; Joshua Matyi; Chelsea Sanders; M Scott DeBerard; Constantine G Lyketsos; JoAnn T Tschanz
Journal:  Int Psychogeriatr       Date:  2018-03-21       Impact factor: 3.878

7.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.

Authors:  Panos Roussos; Pavel Katsel; Peter Fam; Weilun Tan; Dushyant P Purohit; Vahram Haroutunian
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

8.  Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?

Authors:  Afia Akram; James Schmeidler; Pavel Katsel; Patrick R Hof; Vahram Haroutunian
Journal:  Mol Neurodegener       Date:  2010-09-15       Impact factor: 14.195

Review 9.  For whom and for what the definition of severe dementia is useful: an EDCON consensus.

Authors:  E J Byrne; M Benoit; J M Lopez Arrieta; C Geraldi; R Koopmans; Y Rolland; N Sartorius; G Stoppe; P Robert
Journal:  J Nutr Health Aging       Date:  2008-12       Impact factor: 4.075

10.  Uric acid as a CNS antioxidant.

Authors:  Gene L Bowman; Jackilen Shannon; Balz Frei; Jeffrey A Kaye; Joseph F Quinn
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.